

Robert J Didomenico

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6881090/publications.pdf>

Version: 2024-02-01

74
papers

1,237
citations

430874
18
h-index

377865
34
g-index

75
all docs

75
docs citations

75
times ranked

1497
citing authors

#	ARTICLE	IF	CITATIONS
1	Pragmatic Clinical Trial to Improve Patient Experience Among Adults During Transitions from Hospital to Home: the PARTNER study. Journal of General Internal Medicine, 2022, , 1.	2.6	0
2	Patterns Of Renin-Angiotensin-Aldosterone-System Inhibitor Interruption In Patients Hospitalized For Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2022, 28, S20.	1.7	0
3	Stratification of burnout in <scp>healthâ€system</scp> pharmacists during the <scp>COVID</scp>â€19 pandemic: A focus on the ambulatory care pharmacist. JACCP Journal of the American College of Clinical Pharmacy, 2022, 5, 942-949.	1.0	5
4	Influence of digoxin on mortality in patients with atrial fibrillation: Overview of systematic reviews. Pharmacotherapy, 2021, 41, 394-404.	2.6	1
5	Renal Function Assessment and Direct-Acting Oral Anticoagulants Dosing: Are We Entering a New Age?. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008064.	2.2	0
6	Optimizing anticoagulation for patients receiving Impella support. Pharmacotherapy, 2021, 41, 932-942.	2.6	22
7	Residency research training: Need to rethink the prescription for success?. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 664-666.	1.0	2
8	Prevalence of Cardiac Risk Factors in Patients Prescribed Azithromycin before and after the 2012 FDA Warning on the Risk of Potentially Fatal Heart Rhythms. Pharmacotherapy, 2020, 40, 107-115.	2.6	10
9	An opinion paper of the Cardiology Practice and Research Network of the American College of Clinical Pharmacy: Recommendations for training of cardiovascular pharmacy specialists in postgraduate year 2 residency programs. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 95-108.	1.0	1
10	Frequency of Transition to Oral Loop Diuretics Prior to Discharge. Journal of Cardiac Failure, 2020, 26, S93.	1.7	0
11	Risk of cardiac events with azithromycinâ€”A prediction model. PLoS ONE, 2020, 15, e0240379.	2.5	0
12	Comparison of Cardiac Events Associated With Azithromycin vs Amoxicillin. JAMA Network Open, 2020, 3, e2016864.	5.9	6
13	Beyond Heart Failure and Ischemic Heart Disease: A Scoping Review of Novel Uses of Ivabradine in Adults. Pharmacotherapy, 2020, 40, 544-564.	2.6	3
14	Feeling the burn? A systematic review of burnout in pharmacists. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 663-675.	1.0	56
15	Combating pharmacist burnout: A model for critical care clinical pharmacy faculty. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 655-662.	1.0	3
16	Risk of cardiac events with azithromycinâ€”A prediction model. , 2020, 15, e0240379.		0
17	Risk of cardiac events with azithromycinâ€”A prediction model. , 2020, 15, e0240379.		0
18	Risk of cardiac events with azithromycinâ€”A prediction model. , 2020, 15, e0240379.		0

#	ARTICLE	IF	CITATIONS
19	Risk of cardiac events with azithromycinâ€”A prediction model. , 2020, 15, e0240379.		0
20	Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome. Cardiovascular Drugs and Therapy, 2019, 33, 533-546.	2.6	13
21	Design of the patient navigator to Reduce Readmissions (PARtNER) study: A pragmatic clinical effectiveness trial. Contemporary Clinical Trials Communications, 2019, 15, 100420.	1.1	9
22	Frequency of â€œon-labelâ€•use of intravenous diltiazem for rate control in patients with acute-onset atrial fibrillation or atrial flutter. American Journal of Health-System Pharmacy, 2019, 76, 214-220.	1.0	0
23	Survey of Anticoagulation Practices with the Impella Percutaneous Ventricular Assist Device at High-Volume Centers. Journal of Interventional Cardiology, 2019, 2019, 1-6.	1.2	30
24	Costâ€•Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States. Pharmacotherapy, 2018, 38, 520-530.	2.6	21
25	Need for a universal residency application deadline. American Journal of Health-System Pharmacy, 2018, 75, 849-850.	1.0	3
26	Cardiology clinical pharmacy practice: Keep spreading the news!. JACCP Journal of the American College of Clinical Pharmacy, 2018, 1, 54-55.	1.0	0
27	Variability in Anticoagulation Practices With the Impella Percutaneous Ventricular Assist Device: A Survey of High-volume Centers. Journal of Heart and Lung Transplantation, 2018, 37, S310-S311.	0.6	1
28	Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 800-812.	0.9	3
29	Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary Syndrome. Pharmacotherapy, 2017, 37, 877-887.	2.6	7
30	Improving peer review: What reviewers can do. American Journal of Health-System Pharmacy, 2017, 74, 2080-2084.	1.0	18
31	Pharmacologic Considerations in the Management of Patients Receiving Left Ventricular Percutaneous Mechanical Circulatory Support. Pharmacotherapy, 2017, 37, 1272-1283.	2.6	26
32	Improving peer review: What authors can do. American Journal of Health-System Pharmacy, 2017, 74, 2076-2079.	1.0	7
33	Improving peer review: What journals can do. American Journal of Health-System Pharmacy, 2017, 74, 2086-2089.	1.0	13
34	Should Digoxin Continue To Be Used for the Management of Atrial Fibrillation?. Canadian Journal of Hospital Pharmacy, 2017, 70, 391-394.	0.1	4
35	Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 57-63.	0.9	29
36	Letterâ€•The Authors Respond. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 599-600.	0.9	0

#	ARTICLE	IF	CITATIONS
37	Engaging Patients and Caregivers to Design Transitional Care Management Services at a Minority Serving Institution. <i>Journal of Health Care for the Poor and Underserved</i> , 2016, 27, 352-365.	0.8	13
38	CONTEMPORARY TRENDS AND PREDICTORS OF ANTIPLATELET AGENT USE IN PATIENTS WITH ACUTE CORONARY SYNDROME FOLLOWING PERCUTANEOUS CORONARY INTERVENTION. <i>Journal of the American College of Cardiology</i> , 2016, 67, 538.	2.8	0
39	Emerging Therapies for Acute and Chronic Heart Failure. <i>Journal of Pharmacy Practice</i> , 2016, 29, 46-57.	1.0	2
40	Comparison of Practice Patterns Between Inpatient Cardiology Pharmacists With and Without Added Qualifications in Cardiology. <i>Hospital Pharmacy</i> , 2015, 50, 051-058.	1.0	1
41	The Effect of Cardiovascular Credentialed Pharmacists on Process Measures and Outcomes in Myocardial Infarction and Heart Failure. <i>Pharmacotherapy</i> , 2014, 34, 803-808.	2.6	24
42	Interventions to Reduce Rehospitalizations after Chronic Obstructive Pulmonary Disease Exacerbations. A Systematic Review. <i>Annals of the American Thoracic Society</i> , 2014, 11, 417-424.	3.2	91
43	Balance of Academic Responsibilities of Clinical Track Pharmacy Faculty in the United States: A Survey of Select American College of Clinical Pharmacy Practice and Research Network Members. <i>Pharmacotherapy</i> , 2014, 34, 1239-1249.	2.6	16
44	Use of a Simplified Nomogram to Individualize Digoxin Dosing versus Standard Dosing Practices in Patients with Heart Failure. <i>Pharmacotherapy</i> , 2014, 34, 1121-1131.	2.6	9
45	Clinical Pharmacy Services in Heart Failure: An Opinion Paper From the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network. <i>Journal of Cardiac Failure</i> , 2013, 19, 354-369.	1.7	57
46	Discharge Counseling for Patients with Heart Failure or Myocardial Infarction: A Best Practices Model Developed by Members of the American College of Clinical Pharmacy's Cardiology Practice and Research Network Based on the Hospital to Home (<sc>H</sc>2<sc>H</sc>) Initiative. <i>Pharmacotherapy</i> , 2013, 33, 558-580.	2.6	46
47	Clinical Pharmacy Services in Heart Failure: An Opinion Paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network. <i>Pharmacotherapy</i> , 2013, 33, 529-548.	2.6	34
48	Key Articles Related to Complementary and Alternative Medicine in Cardiovascular Disease: Part 2. <i>Pharmacotherapy</i> , 2011, 31, 1041-1041.	2.6	1
49	Comparison of Rate Control versus Rhythm Control for Management of Atrial Fibrillation in Patients with Coexisting Heart Failure: A Cost-Effectiveness Analysis. <i>Pharmacotherapy</i> , 2011, 31, 552-565.	2.6	16
50	Selection of drug-laboratory result pairs for an inpatient asynchronous alert program: Results of a Delphi survey. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 407-414.	1.0	3
51	Letter by DiDomenico et al Regarding Article, "Recent National Trends in Readmission Rates After Heart Failure Hospitalization": Circulation: Heart Failure, 2010, 3, e13; author reply e17.	3.9	2
52	Predictors of Diuretic Resistance in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, S80.	1.7	0
53	Impact of Treatment Guidelines on Clinical and Economic Outcomes of Acute Decompensated Heart Failure. <i>Annals of Pharmacotherapy</i> , 2008, 42, 327-333.	1.9	6
54	Hospital Policies for Treatment of Acute Decompensated Heart Failure. <i>Annals of Pharmacotherapy</i> , 2007, 41, 562-567.	1.9	5

#	ARTICLE	IF	CITATIONS
55	A New and Simple Dosing Algorithm for Digoxin in Patients with Heart Failure. <i>Journal of Cardiac Failure</i> , 2006, 12, S85.	1.7	0
56	The Effects of Nesiritide and Other Vasoactive Agents on Renal Function. <i>Journal of Cardiac Failure</i> , 2006, 12, S88.	1.7	0
57	Mechanisms, Manifestations, and Management of Digoxin Toxicity in the Modern Era. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 77-86.	2.2	81
58	Recent Developments in Antithrombotic Therapy: Will Sodium Warfarin Be a Drug of the Past?. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2006, 1, 307-316.	1.5	10
59	A Method of Determining the Dose of Digoxin for Heart Failure in the Modern Era. <i>Archives of Internal Medicine</i> , 2006, 166, 2539.	3.8	32
60	CLINICAL OUTCOMES OF PATIENTS ON CLOPIDOGREL WITH A HEMORRHAGIC EPISODE.. <i>Critical Care Medicine</i> , 2006, 34, A63.	0.9	0
61	Use of Recombinant Activated Factor VII for Bleeding Following Operations Requiring Cardiopulmonary Bypass. <i>Chest</i> , 2005, 127, 1828-1835.	0.8	55
62	A Trial of Automated Decision Support Alerts for Contraindicated Medications Using Computerized Physician Order Entry. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2005, 12, 269-274.	4.4	110
63	Pharmacologic Strategies for Prevention of Atrial Fibrillation After Open Heart Surgery. <i>Annals of Thoracic Surgery</i> , 2005, 79, 728-740.	1.3	51
64	Initiating Warfarin Therapy: 5 mg versus 10 mg. <i>Annals of Pharmacotherapy</i> , 2004, 38, 2115-2121.	1.9	17
65	Guidelines for Acute Decompensated Heart Failure Treatment. <i>Annals of Pharmacotherapy</i> , 2004, 38, 649-660.	1.9	78
66	A Trial of Automated Safety Alerts for Inpatient Digoxin Use with Computerized Physician Order Entry. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2004, 11, 270-277.	4.4	44
67	Randomized Trial of Warfarin Nomograms. <i>Annals of Internal Medicine</i> , 2004, 140, 489.	3.9	0
68	Did contrast nephropathy in RAPID really occur?. <i>Journal of the American College of Cardiology</i> , 2003, 42, 2167.	2.8	1
69	Cocaine-Induced Channelopathies: Emerging Evidence on the Multiple Mechanisms of Sudden Death. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2002, 7, 195-202.	2.0	64
70	Reimbursement mechanisms for glycoprotein IIb/IIIa-receptor inhibitors. <i>American Journal of Health-System Pharmacy</i> , 2002, 59, S37-S42.	1.0	0
71	Preventing exacerbation of an ADE with automated decision support. <i>Journal of Healthcare Information Management: JHIM</i> , 2002, 16, 44-9.	0.1	4
72	Impact of the Cost of Prescription Drugs on Clinical Outcomes in Indigent Patients with Heart Disease. <i>Pharmacotherapy</i> , 2001, 21, 1455-1463.	2.6	53

#	ARTICLE	IF	CITATIONS
73	Analysis of the Use of Digoxin Immune Fab for the Treatment of Non-Life-Threatening Digoxin Toxicity. Journal of Cardiovascular Pharmacology and Therapeutics, 2000, 5, 77-85.	2.0	15
74	New Antithrombotics for the Intensive Care Unit Setting: GP IIb/IIIa Inhibitors, Low-Molecular-Weight Heparins, and Direct Thrombin Inhibitors. Critical Care Nursing Quarterly, 2000, 22, 61-74.	0.8	2